$RAPP News

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?

Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52

Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?

Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target

Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate